Cellular and T cell engager Immunotherapy
Infections and Immune Reconstitution in the Phase 3 CARTITUDE-4 Trial of Ciltacabtagene Autoleucel vs Standard Care in Patients with Lenalidomide-Refractory Multiple Myeloma (MM) and 1–3 Prior Lines
Niels W.C.J van de Donk, MD, PhD (he/him/his)
Professor
Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Department of Hematology, Amsterdam, Netherlands, and Cancer Center Amsterdam, Amsterdam, Netherlands
Amsterdam, Noord-Holland, Netherlands